These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 4706860)

  • 1. Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
    Donnelly EF; Chase TN
    Dis Nerv Syst; 1973 Feb; 34(2):119-23. PubMed ID: 4706860
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evolution of intellectual potential and memory in Parkinsonism patients treated with L-dopa].
    Vernet JP; Novi M; Sevilla M; Becle J; Lavagna J; Darcourt G
    Ann Med Psychol (Paris); 1973 Mar; 1(3):413-27. PubMed ID: 4722004
    [No Abstract]   [Full Text] [Related]  

  • 3. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of L-dopa on mental functions in parkinsonism].
    Violon A; Peypers J; Rappel M
    Acta Psychiatr Belg; 1972 Mar; 72(2):168-84. PubMed ID: 5056014
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of L-dopa on individual symptoms of parkinsonism.
    Boshes B; Blonsky ER; Arbit J; Klein K
    Trans Am Neurol Assoc; 1969; 94():229-31. PubMed ID: 5374443
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinsonism, L-dopa, and intelligence.
    Loranger AW; Goodell H; McDowell FH; Lee JE; Sweet RD
    Am J Psychiatry; 1973 Dec; 130(12):1386-9. PubMed ID: 4754685
    [No Abstract]   [Full Text] [Related]  

  • 7. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM; Olanow CW; Spencer A
    Trans Am Neurol Assoc; 1973; 98():301-3. PubMed ID: 4594189
    [No Abstract]   [Full Text] [Related]  

  • 8. [The Rey complex picture test in evaluation of some effects induced by treatment with L-dopa in patients with parkinsonism].
    Megna GF; Puca FM; Micalizzi V; Leggiadro N; Di Rosa AE
    Acta Neurol (Napoli); 1971; 26(4):473-83. PubMed ID: 4943712
    [No Abstract]   [Full Text] [Related]  

  • 9. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

  • 10. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM; Miller S; Gunder M
    Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 12. [General intelligence of patients with parkinsonism during L-dopa medication (author's transl)].
    Jacobi P; Fischer PA; Schneider E
    Arch Psychiatr Nervenkr (1970); 1974; 218(2):125-40. PubMed ID: 4817897
    [No Abstract]   [Full Text] [Related]  

  • 13. [Study of 30 parkinsonian patients treated for 6 months with L-Dopa].
    Barbizet J; Duizabo P
    Therapie; 1972; 27(1):133-40. PubMed ID: 5017549
    [No Abstract]   [Full Text] [Related]  

  • 14. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
    Almici GM; Sbarbaro V
    Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
    [No Abstract]   [Full Text] [Related]  

  • 15. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism].
    Gerstenbrand F; Grünberger J; Schubert H
    Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects].
    Geissbuhler F; Eisenring JJ; Friedli P; Bartholini G; Tissot R
    Encephale; 1972; 61(2):127-48. PubMed ID: 4634903
    [No Abstract]   [Full Text] [Related]  

  • 17. [Toulouse-Piéron test in patients with Parkinsonism treated with L-dopa].
    Megna GF; Puca FM; Leggiadro N; Micalizzi V; Pigneri MT
    Acta Neurol (Napoli); 1973; 28(2):213-22. PubMed ID: 4575429
    [No Abstract]   [Full Text] [Related]  

  • 18. L-dopa: effect on highest integrative functions in Parkinsonism.
    Guthrie TC; Dunbar HS; Weider A
    Trans Am Neurol Assoc; 1970; 95():250-2. PubMed ID: 5514382
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ
    N Y State J Med; 1974 Jan; 74(1):47-51. PubMed ID: 4591989
    [No Abstract]   [Full Text] [Related]  

  • 20. [Our first observations on Parkinson's disease or parkinsonian syndromes treated with L-dopa].
    Boudouresques J; Khalil R; Vigouroux RA; Gosset A; Daniel F; Dufour H
    Mars Med; 1971; 108(2):85-9. PubMed ID: 5548385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.